Talk:Enzalutamide
| This is the talk page for discussing improvements to the Enzalutamide article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Enzalutamide.
|
 | This article is rated B-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
Section
Needs a vector (SVG) version of chemical. —Preceding unsigned comment added by 140.226.190.83 (talk) 16:06, 7 September 2010 (UTC)
Phase III trials
Here are the 2 journal publications of the phase III trial, which should go in the entry. The NEJM article is free online.
http://www.ncbi.nlm.nih.gov/pubmed/22894553
http://www.ncbi.nlm.nih.gov/pubmed/23300275
--Nbauman (talk) 11:22, 18 October 2013 (UTC)
Off-label Hairloss treatment
It's being used as a topical hair loss treatment by Alopecia Androgenetica sufferers...
https://www.alopezie.de/fud/index.php/t/30791/
--78.51.19.35 (talk) 00:40, 30 November 2017 (UTC)
Priority Review for combination with ADT for some prostate cancer
Could mention Priority Review and PROSPER trial [1] in a Clinical Trials section or at least in History ? Summarise : "The sNDA is based on data from the phase 3 PROSPER trial in which the combination of Xtandi and androgen deprivation therapy (ADT) reduced the risk of metastases or death by 71 percent compared with ADT alone for patients with nonmetastatic CRPC. ... the median metastasis-free survival (MFS) was 36.6 months with Xtandi plus ADT versus 14.7 months with ADT alone." ... "There was a 93 percent reduction in the risk of PSA progression in the Xtandi arm compared with ADT alone. The median time to PSA progression in the Xtandi group was 37.2 months compared with 3.9 months for ADT alone. The time to next antineoplastic therapy was extended by a median of 21.9 months with Xtandi versus ADT alone. Men enrolled in the Xtandi arm required a new therapy after a median of 39.6 months compared with 17.7 months in the placebo group, representing a 79 percent reduction in the risk of requiring a new therapy." - Rod57 (talk) 17:29, 23 March 2018 (UTC)